[go: up one dir, main page]

MX2012003408A - Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. - Google Patents

Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.

Info

Publication number
MX2012003408A
MX2012003408A MX2012003408A MX2012003408A MX2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A
Authority
MX
Mexico
Prior art keywords
abt
crystalline forms
solvates
related diseases
protein related
Prior art date
Application number
MX2012003408A
Other languages
English (en)
Inventor
Thomas B Borchardt
Paul J Brackemeyer
Geoff G Z Zhang
Nathaniel D Catron
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2012003408A publication Critical patent/MX2012003408A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La base libre de ABT-263 y formas cristalinas de la misma son ingredientes farmacéuticos activos adecuados para composiciones farmacéuticas útiles en el tratamiento de una enfermedad caracterizada por sobre-expresión de una o más proteínas de familia de BcI-2 anti-apoptóticas, por ejemplo, cáncer.
MX2012003408A 2009-09-20 2010-09-15 Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. MX2012003408A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24405109P 2009-09-20 2009-09-20
PCT/US2010/048949 WO2011034934A1 (en) 2009-09-20 2010-09-15 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases

Publications (1)

Publication Number Publication Date
MX2012003408A true MX2012003408A (es) 2012-08-03

Family

ID=43064468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003408A MX2012003408A (es) 2009-09-20 2010-09-15 Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.

Country Status (15)

Country Link
US (2) US8362014B2 (es)
EP (1) EP2477972A1 (es)
JP (2) JP2013505249A (es)
KR (1) KR20120085781A (es)
CN (2) CN105820138A (es)
AU (1) AU2010295717B2 (es)
BR (1) BR112012006252A2 (es)
CA (1) CA2771984A1 (es)
IL (1) IL218403A0 (es)
MX (1) MX2012003408A (es)
NZ (1) NZ598461A (es)
RU (1) RU2551376C2 (es)
TW (1) TWI488853B (es)
WO (1) WO2011034934A1 (es)
ZA (1) ZA201202891B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3594237A1 (en) * 2008-11-07 2020-01-15 Amgen Research (Munich) GmbH Treatment of pediatric acute lymphoblastic leukemia
ES2727585T3 (es) * 2008-11-07 2019-10-17 Amgen Res Munich Gmbh Tratamiento de leucemia linfoblástica aguda
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
CN105820138A (zh) 2009-09-20 2016-08-03 Abbvie 公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
SG10201500152UA (en) 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2958916B1 (en) * 2013-02-21 2018-09-12 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
CN105377289A (zh) * 2013-04-21 2016-03-02 耶达研究及发展有限公司 用于下调Bcl-xL和/或Bcl-w的活性和/或量的试剂
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
SG11201606239UA (en) * 2014-01-28 2016-08-30 Buck Inst For Res On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20170202782A1 (en) * 2014-04-06 2017-07-20 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738B (zh) * 2018-08-29 2020-10-16 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
JP7417356B2 (ja) 2019-01-25 2024-01-18 株式会社ソニー・インタラクティブエンタテインメント ロボット制御システム
MX2022005375A (es) 2019-11-05 2022-10-07 Abbvie Inc Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713507A (en) 1948-10-04 1955-07-19 Garlinghouse Brothers Concrete bucket
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7075365B1 (en) 2004-04-22 2006-07-11 Altera Corporation Configurable clock network for programmable logic device
NZ561609A (en) * 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
US7842681B2 (en) * 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
JP4202380B2 (ja) * 2006-10-17 2008-12-24 シャープ株式会社 画像形成装置
CA2708223A1 (en) * 2007-12-06 2009-06-11 Andrew Krivoshik Oral compositions of abt-263 for treating cancer
CN101220008B (zh) * 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8140876B2 (en) * 2009-01-16 2012-03-20 International Business Machines Corporation Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer
JP2010259520A (ja) * 2009-04-30 2010-11-18 Motoji Ono 搬送機構、トレッドミル及びコンベア
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8291422B2 (en) * 2009-05-11 2012-10-16 Bbn Technologies Corp. Energy-aware computing environment scheduler
US20110047552A1 (en) * 2009-05-11 2011-02-24 Raytheon Bbn Technologies Corp. Energy-aware process environment scheduler
CN105820138A (zh) 2009-09-20 2016-08-03 Abbvie 公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
CN101798292A (zh) * 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Also Published As

Publication number Publication date
TWI488853B (zh) 2015-06-21
US20110294811A1 (en) 2011-12-01
JP2015232006A (ja) 2015-12-24
ZA201202891B (en) 2013-09-25
EP2477972A1 (en) 2012-07-25
CA2771984A1 (en) 2011-03-24
JP2013505249A (ja) 2013-02-14
AU2010295717A1 (en) 2012-03-22
NZ598461A (en) 2013-12-20
CN102695702A (zh) 2012-09-26
US8362014B2 (en) 2013-01-29
WO2011034934A1 (en) 2011-03-24
KR20120085781A (ko) 2012-08-01
BR112012006252A2 (pt) 2017-05-23
AU2010295717B2 (en) 2014-09-11
TW201116526A (en) 2011-05-16
RU2012115851A (ru) 2013-10-27
US20110071151A1 (en) 2011-03-24
IL218403A0 (en) 2012-04-30
CN105820138A (zh) 2016-08-03
US8513243B2 (en) 2013-08-20
RU2551376C2 (ru) 2015-05-20

Similar Documents

Publication Publication Date Title
MX2012003408A (es) Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
MX2011011511A (es) Sal de abt-263 y fomas en estado solido de la misma.
PH12015500297B1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
PH12015502017A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune disease
MX2011007684A (es) Agentes inductores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
PH12012501071A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12015502792A1 (en) Crystalline bromodomain inhibitors
UA107706C2 (uk) Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
WO2010083441A3 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TN2011000263A1 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
PH12016501126A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ598694A (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
PT1687305E (pt) Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
CL2011000124A1 (es) Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer.
NZ596047A (en) Stabilized lipid formulation of apoptosis promoter
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
MY150931A (en) Substituted oxazolidinones and their use
MX2012007325A (es) Capsula de abt-263.
UA107655C2 (uk) Селективні інгібітори антиапоптичних білків bcl-2 для лікування раку і імунних захворювань
UA107351C2 (en) Stabilized lipid formulation of apoptosis promoter

Legal Events

Date Code Title Description
GB Transfer or rights